Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: A single-institution experience

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 6, 2011, Pages 507-511

  Lebovic, Daniel ^a   Zhang, Ling ^a   Alsina, Melissa ^a   Nishihori, Taiga ^a   Shain, Kenneth H ^a   Sullivan, Daniel ^a   Ochoa Bayona, Jose L ^a   Kharfan Dabaja, Mohamed A ^b   Baz, Rachid ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Allogeneic transplantation; Autologous transplantation; Bortezomib; Overall survival; Plasma cell leukemia

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; MELPHALAN;

ADULT; AGED; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LONG TERM SURVIVAL; MALE; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84860629972     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.06.010     Document Type: Review

References (18)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol 2. 4th ed. Geneva, Switzerland: IARC Press; 2008.
2. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974; 133:813-8.
3. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12:1977-82. (Pubitemid 28554471)
4. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032-37. (Pubitemid 29067869)
5. Ramsingh G, Mehan P, Luo J, et al. Plasma cell leukemia: A SEER database analysis. J Clin Oncol 2009; 27(suppl):abstract 8605. Available at: http://www.asco.org. Accessed July 3, 2011.
6. Peijing Q, Yan X, Yafei W, et al. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol 2009; 121:47-51.
7. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22:1044-52. (Pubitemid 351689887)
8. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001; 97:822-5. (Pubitemid 32113422)
9. Chang H, Qi X, Yeung J, et al. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009; 33:259-62.
10. Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109:2285-90. (Pubitemid 46801559)
11. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467-73. (Pubitemid 44264086)
12. Cha CH, Park CJ, Huh JR, et al. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol 2007; 118:178-82. (Pubitemid 350014911)
13. Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous ítem cell transplantation. Haematologica 2010; 95:804-9.
14. Mahindra A, Vesole D, Kalaychio ME, et al. Autologous hematopoietic stem cell transplantation (HCT) is a safe and effective treatment for primary plasma cell leukemia: the CIBMTR experience. Blood 2009; 114:abstract 532.
15. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78:288-94. (Pubitemid 40471121)
16. Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011; 22:1628-35.
17. Finnegan DP, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47:1670-3. (Pubitemid 44364036)
18. Alegre A, Aguado B, Lahuerta JJ, et al. Clinical efficacy of bortezomib based therapy in plasma cell leukemias. Blood 2007; 110:abstract 2726.